Immunogenicity and protective efficacy of an inactivated SFTS vaccine candidate in mice  

作　　者：Aqian Li Xinxian Dai Lei Chen Lin Liu Chuan Li Yang Liu Wei Wu Xiaoxia Huang Jiandong Li Shiwen Wang Mifang Liang Xiuling Li Dexin Li 

机构地区：[1]Department of Viral Hemorrhagic Fever,National Institute for Viral Disease Control and Prevention,China CDC,Beijing 102206,China b [2]National Vaccine and Serum Institute,Beijing 102206,China [3]Suzhou Institute of Systems Medicine,Suzhou 215123,China [4]China CDC-WIV Joint Research Center for Emerging Diseases and Biosafety,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan 430071,China

出　　处：《Biosafety and Health》2022年第1期45-52,共8页生物安全与健康（英文）

基　　金：This study was supported by the National Major Science and Technology Project of China(2018ZX10711001 and 2013ZX09102029);The funders had no role in study design,data collection and analysis,decision to publish,or preparation of the manuscript.

摘　　要：Severe fever with thrombocytopenia syndrome(SFTS),caused by a novel identified bunyavirus SFTS virus(SFTSV),was an emerging viral infectious disease that was firstly reported in China.There are no licensed vaccines and therapeutics against SFTSV currently.B‐Propiolactone(BPL)inactivated whole virions of SFTSV strain AH12 were prepared as experimental vaccine in different antigen dose with or without Al(OH)3 adjuvant.The experimental SFTS vaccine was a satisfying immunogen,which could efficiently trigger the development of high levels of SFTSV NP‐specific IgG antibodies and neutralizing antibodies against SFTSV Strain HB29 in BALB/c and C57/BL6 mice,and could induce SFTS virus‐specific cellular immune responses to a certain extent.A single dose of vaccine was immunogenically insufficient in BALB/c mice;the second and third dose resulted in significant boost in antibody response.The use of Al(OH)3 adjuvant resulted in higher antibody titers.The mediate‐dose of vaccine could induce as high and equivalent level of antibody titer as that of high‐dose.The experimental SFTS vaccine in mediate‐and high antigen dose with adjuvant resulted in solid protection of C57/BL6 mice against wild‐type SFTSV challenge with markedly accelerated virus clearance from blood and spleen compared with controls.The experimental SFTS vaccine prepared in this study could efficiently elicit virus specific humoral and cellular immune responses in both BALB/c and C57/BL6 mice,and could protect C57/BL6 mice against SFTS virus challenge.These results supplied evidence that inactivated vaccine was a promising vaccine candidate for the prevention of SFTSV infection.

关 键 词：SFTS virus Inactivated vaccine IMMUNOGENICITY Protective efficacy 

分 类 号：R392[医药卫生—免疫学]